TFF Pharmaceuticals, Inc. (TFFP)
Stock Price:
$13.37 USD
-0.91 (-6.37%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
After-hours: $12.71 -0.66 (-4.94%) Oct 28, 4:54 PM
Key Info
| Market Cap |
297.97M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-15.11M |
| Shares Out |
22.29M |
| EPS (ttm) |
-2.60 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$13.37 |
| Previous Close |
$14.28 |
| Change ($) |
-0.91 |
| Change (%) |
-6.37% |
| Day's Open |
13.90 |
| Day's Range |
12.96 - 13.98 |
| Day's Volume |
314,286 |
| 52-Week Range |
3.44 - 19.00 |
More Stats
| Market Cap |
297.97M |
| Enterprise Value |
276.04M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
22.29M |
| Float |
16.70M |
| EPS (basic) |
-4.60 |
| EPS (diluted) |
-2.60 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
370,808 |
| Short Ratio |
0.98 |
| Short % of Float |
2.22% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
15.13 |
| Revenue |
n/a |
| Operating Income |
-15.27M |
| Net Income |
-15.11M |
| Free Cash Flow |
n/a |
| Net Cash |
21.92M |
| Net Cash / Share |
0.98 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-52.53% |
| ROE |
-88.84% |
| ROIC |
4,170.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$20.50*
(53.33% upside)
Low
18.0
Current: $13.37
High
23.0
Target: 20.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -11.99 | -3.90 | -0.18 |
| Net Income | -11.87 | -3.84 | -0.18 |
| Shares Outstanding | 6.90 | 3.48 | - |
| Earnings Per Share | -5.31 | -1.31 | - |
| Operating Cash Flow | -11.22 | -2.13 | -0.19 |
| Free Cash Flow | -11.22 | -2.13 | -0.19 |
| Cash & Equivalents | 28.09 | 10.26 | - |
| Net Cash / Debt | 28.09 | 10.26 | - |
| Assets | 29.19 | 10.40 | - |
| Liabilities | 1.54 | 1.16 | - |
| Book Value | 27.64 | -3.24 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
TFF Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
4 |
| CEO |
Glenn R. Mattes |
Stock Information
| Ticker Symbol |
TFFP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: TFFP |
| IPO Date |
October 25, 2019 |
Description
TFF Pharmaceuticals, an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company has a research collaboration with the University of Georgia's Center for Vaccines and Immunology (CVI), along with the University of Texas at Austin (UT Austin), to evaluate the immunogenicity of universal influenza vaccines; and cooperative research and development agreement with United States Army Medical Research Institute of Infectious Diseases for use of its thin film freezing technology platform. TFF Pharmaceuticals, Inc. was founded in 2018 and is based in Austin, Texas.